ReviewDrugs2019
Engineering for Success: Approaches to Improve Chimeric Antigen Receptor T Cell Therapy for Solid Tumors.
Review in Drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients.Journal for immunotherapy of cancer · 2020Trial
- Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer.Nature communications · 2025Article
- Car T Cells in Solid Tumors: Overcoming Obstacles.International journal of molecular sciences · 2024Review
- Trogocytosis of CAR molecule regulates CAR-T cell dysfunction and tumor antigen escape.Signal transduction and targeted therapy · 2023Article
- Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating.Cancer discovery · 2023Article
- Article
- IL-21 Optimizes the CAR-T Cell Preparation Through Improving Lentivirus Mediated Transfection Efficiency of T Cells and Enhancing CAR-T Cell Cytotoxic Activities.Frontiers in molecular biosciences · 2021Article
- Generation of an NFκB-Driven Alpharetroviral "All-in-One" Vector Construct as a Potent Tool for CAR NK Cell Therapy.Frontiers in immunology · 2021Article
- The Confluence of Innovation in Therapeutics and Regulation: Recent CMC Considerations.Journal of pharmaceutical sciences · 2020Review
- The Application of CAR-T Cells in Haematological Malignancies.Archivum immunologiae et therapiae experimentalis · 2020Review
- Rewriting History: Epigenetic Reprogramming of CD8Trends in immunology · 2020Review
- Tuning the Antigen Density Requirement for CAR T-cell Activity.Cancer discovery · 2020Article
- Design and Characterization of an "All-in-One" Lentiviral Vector System Combining Constitutive Anti-GCancers · 2020Article
- Current status and hurdles for CAR-T cell immune therapy.Blood science (Baltimore, Md.) · 2019Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
While impressive clinical responses have been observed using chimeric antigen receptor (CAR) T cells targeting CD19+ hematologic malignancies, limited clinical benefit has been observed using CAR T cells for a variety of solid tumors. Results of clinical studies have highlighted several obstacles which CAR T cells face in the context of solid tumors, including insufficient homing to tumor sites, lack of expansion and persistence, encountering a highly immunosuppressive tumor microenvironment, and heterogeneous antigen expression. In this review, we review clinical outcomes and discuss strategies to improve the antitumor activity of CAR T cells for solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.